The database is scheduled to be unveiled at the 2004 Tandem Bone Marrow Transplant Meetings in Orlando, FL. See http://www.
With the availability of this new database, researchers can generate and test hypotheses on the role of donor matching in blood and marrow stem cell transplants. The database also provides survival rates of people who received cell grafts, helping doctors and their patients evaluate the potential risks and benefits of transplantation in treating disorders such as leukemia.
"This important new resource will make it easier for physicians to predict outcomes of blood and marrow stem cell transplants and to tailor therapies to the specific needs of their patients," says Anthony S. Fauci, M.D., director of NIAID.
"This effort is part of a long-range plan at NIAID to develop and disseminate genetic tools that provide greater predictive value for donor matching than current methods," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation.
The database contains scientific and clinical data on the relationship between major histocompatibility complex (MHC) genes and transplantation. Human MHC genes encode molecules on the surface of cells commonly known as human leukocyte antigens or HLA. These molecules alert the immune system to the presence of anything foreign in the body. MHC genes vary widely throughout the general population, so blood and marrow stem cells from one person may be rejected when transplanted into a recipient who does not closely match the donor's MHC type.
The database allows scientists and physicians to search for information in a variety of ways. For example, a doctor can look for the results of transplants involving a recipient with a given set of MHC genes and an unrelated donor with another set of MHC genes.
"The widespread availability of clinical transplant results may help researchers recognize the limits of MHC mismatching," says Effie Wang Petersdorf, M.D., professor at the University of Washington School of Medicine and Member of the Fred Hutchinson Cancer Research Center, who leads the team of researchers and clinicians contributing transplant data to the project. "If we know which MHC mismatches may be tolerable, it may increase the use of transplantation as a curative therapy for patients who do not have a matched donor."
To ensure patient and donor privacy, none of the clinical information in the database contains personal identifiers such as birth dates. The available data include patient and donor MHC types, ethnicity, age and gender as well as the description of the transplant, the disease diagnosis and the number of days the recipient survived after the transplant.
This transplant database is part of a broader MHC database maintained by NCBI, and part of a larger effort supported by NIAID. The MHC database presents information from the International Histocompatibility Working Group in Hematopoietic Cell Transplantation, an effort spearheaded by NIAID with additional support from the Juvenile Diabetes Research Foundation; other NIH components, including the National Cancer Institute, the National Human Genome Research Institute, and the National Institute of Diabetes and Digestive and Kidney Diseases; and the Centers for Disease Control and Prevention.
NIAID, NLM and NCBI are components of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.
Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.